Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1519-1525

  Simonsen, Lena E ^a,b   Wählby, Ulrika ^a   Sandström, Marie ^a   Freijs, Agneta ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Box 580   (Sweden)

Author keywords

5 Fluorouracil; Epirubicin; Haematological toxicity; Pharmacokinetics; Schedule dependence

Indexed keywords

EPIRUBICIN; FLUOROURACIL; FLURABLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BODY WEIGHT; EPIRUBICIN; FLUOROURACIL; LEUKOCYTE COUNT; MALE; PLATELET COUNT; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0343962164     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH and Wrigley PF: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340, 1989.
2. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B and Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
3. Robert J: Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines. Cancer Chemother Pharmacol 32: 99-102, 1993.
4. Pratt WB, Ruddon RW, Ensminger WD and Maybaum J: Anti-metabolites. In: The anticancer drugs (Pratt WB, Ruddon RW, Ensminger WD and Maybaum J, eds). New York, Oxford University Press Inc., 1994, pp 69-107.
5. Looney WB, Macleod MS and Hopkins HA: Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts. Br J Cancer 37: 841 -848, 1978.
6. Koks CH, van der Kam HJ and Brouwers JR: A simple high pressure liquid chromatographic method for the determination of fluorouracil to monitor patients on regional infusion for hepatic metastases. Pharm Weekbl Sci 12: 154-157, 1990.
7. Launay MC, Milano G, Iliadis A, Frenay M and Namer N: A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br J Cancer 60: 89-92, 1989.
8. Robert J: Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liquid Chromatogr 3: 1561-1572, 1980.
9. Israel M, Pegg WJ, Wilkinson PM and Garnick MB: Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liquid Chromatogr 1: 795-809, 1978.
10. Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog ML, Bergh J and Karlsson MO: Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 14: 1581-1588, 1996.
11. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M and Sinkule JA: Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxoruhicin. Clin Pharmacol Ther 45: 340-347, 1989.
12. Beal SL and Sheiner LB: NONMEM Users Guides. San Fransisco, NONMEM project group, University of California, 1992.
13. Karlsson MO, Jonsson EN, Wiltse CG and Wade JR: Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26: 207-246, 1998.
14. Jonsson EN and Karlsson MO: Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64, 1999.
15. Sandström M, Simonsen LE, Freijs A and Karlsson MO: The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemother Pharmacol 44: 469-474, 1999.
16. Karlsson MO, Molnar V, Bergh J, Freijs A and Larsson R: A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63: 11 -25, 1998.
17. Jarugula VR, Lam SS and Boudinot FD: Nonlinear pharmacokinetics of 5-fluorouracil in rats. J Pharm Sci 86: 756-758, 1997.
18. Dilloway MR and Lant AF: Effect of H2-receptor antagonists on the pharmacokinetics of 5-fluorouracil in the rat and monkey. Biopharm Drug Dispos 12: 17-28, 1991.
19. Harris BE, Song RL, Soong SJ and Diasio RB: Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res 49: 6610-6614, 1989.
20. Aardal NP, Laerum OD: Circadian variations in mouse bone marrow, Exp Hematol 11: 792-801, 1983.
21. Abrahamsen JF, Smaaland R, Sothern RB and Laerum OD: Circadian cell cycle variations of erythro-and myelopoiesis in humans. Eur J Haematol 58: 333-345, 1997.
22. van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong APJM. Wattel E, Peters GJ and Lankelma J: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48: 6956-6961, 1988.
23. Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS and Mouridsen HT: A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28: 465-469, 1991.
24. Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Sigman LM, Engisch KL and Aisner J: Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46: 1513-1520, 1986.
25. Sobrero AF, Aschele C and Bertino JR: Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15: 368-381, 1997.